A
AtomVie Global Radiopharma
Global Contract Development and manufacturing organization
About AtomVie Global Radiopharma
AtomVie is a startup operating in the healthcare sector, specifically in the production and supply of lutetium-177 (Lu-177), a radioisotope commonly used in targeted radiotherapy. The company has developed a new production technology for non-carrier added (n.c.a.) Lu-177, in collaboration with Isotopia, to ensure a stable and reliable supply. This technology has been successfully integrated into AtomVie's current Good Manufacturing Practice (GMP) facility, which is a system for ensuring that products are consistently produced and controlled according to quality standards.
AtomVie's primary clients are healthcare providers and institutions that require Lu-177 for radiotherapeutic treatments. The company operates in the global healthcare market, with a focus on meeting increasing supply demands in North America.
The business model of AtomVie is based on the production and distribution of Lu-177. The company generates revenue by selling this radioisotope to healthcare providers. AtomVie has already shipped its first doses of commercial n.c.a. Lu-177, indicating a successful start to its operations.
The company also places a strong emphasis on diversity and inclusivity, as evidenced by the testimonials of its employees. This not only creates a positive work environment but also contributes to the innovative and dynamic nature of the startup.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2015
- Headquarters
- Hamilton, Canada
- Employees
- 154
- Open positions
- 11
- Dealroom signal
- 52.1/100
- Industry
- Health
- Sub-industry
- BioTechnology, Medical Devices
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Spinout, Radioisotope Therapeutics, Techbio, biomanufacturing, DT and LS, science-based
- Technology
- Deep Tech
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Jun 2023 | $90M | $360M | Avego | ↗ |
| SERIES AOther financing | Aug 2022 | $40M | $160M | Avego | ↗ |
Growth signals
Latest recorded traffic for AtomVie Global Radiopharma is 3.4K monthly website visits, down 42.4% over the last three months. AtomVie Global Radiopharma's team grew 5.5% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Avego
Other known investors1 additional known investor
Centre For Probe Development And Commercialization
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about AtomVie Global Radiopharma on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See AtomVie Global Radiopharma’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.